Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Outpatient administration of cilta-cel may yield similar effectiveness and safety outcomes relative to inpatient (IP) administration while significantly reducing IP resource use (fewer IP days/pt/mo (2.4 vs. 6.6; p<0.001)).”
Title: Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings
Authors: Murali Janakiram, Lin Fan, Sabyasachi Ghosh, Victoria Alegria, Matthew Perciavalle, Bruno Emond, Jessica Maitland, Todd Bixby, Saurabh P. Nagar, Zaina P. Qureshi, Danai Dima
You can read the Full Article in Journal of Medical Economics.
You can find other articles featuring Robert Z. Orlowski on OncoDaily.
